Royalty Pharma Plc
(NASDAQ : RPRX)

... ...
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 2.71%170.480.7%$1335.07m
PFEPfizer Inc. 0.07%37.310.9%$1185.97m
LLYEli Lilly & Co. 0.31%213.001.1%$1039.28m
ABBVAbbVie, Inc. -1.53%108.811.9%$741.94m
AZNAstraZeneca Plc 0.80%54.441.2%$706.03m
BMYBristol-Myers Squibb Co. -0.60%64.441.0%$699.94m
MRKMerck & Co., Inc. -1.06%80.290.7%$695.02m
ARCTArcturus Therapeutics Holdings, Inc. -6.41%64.990.0%$214.40m
NVSNovartis AG -2.60%95.910.2%$197.19m
VTRSViatris, Inc. -0.81%17.090.0%$191.78m
RPRXRoyalty Pharma Plc 2.56%52.820.2%$182.74m
GSKGlaxoSmithKline Plc 0.82%39.240.2%$162.70m
GRTSGritstone Oncology, Inc. -13.83%20.560.0%$157.84m
SNYSanofi -0.97%49.150.2%$137.10m
TAKTakeda Pharmaceutical Co., Ltd. -0.98%18.190.0%$84.77m

Company Profile

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.